Sirtex, a global healthcare business with offices in the United States, Australia, Europe and Asia, announced on Monday that it has successfully performed the first procedure of selective internal radiation therapy using SIR-Spheres Y-90 resin microspheres for a patient with hepatocellular carcinoma in China, effective 28 September 2021.
The company has achieved this milestone with the support of its shareholder China Grand Pharmaceutical and Healthcare Holdings Limited.
Dr Jiahong Dong, a specialist in hepatobiliary pancreatic surgery and liver transplantation, and his team at Boao Super Hospital in the Hainan Province have carried out the procedure.
In November 2020, the National Medical Products Administration (NMPA) of the People's Republic of China accepted the Sirtex new drug application (NDA) of SIR-Spheres Y-90 resin microspheres for the treatment of colorectal cancer liver metastases.
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Exact Sciences secures Medicare coverage for Oncodetect MRD test in colorectal cancer
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
Celltrion USA launches denosumab biosimilars STOBOCLO and OSENVELT (denosumab-bmwo) in US
HotSpot Therapeutics presents small molecule CBM signalosome inhibitor program data
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer